Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 131 full-time employees. The company went IPO on 2015-11-05. The firm is engaged in the discovery and development of medicines for the treatment of cancer. The Company’s pipeline consists of small molecule product candidates that target cancer signaling pathways. The Company’s products candidate includes Ziftomenib, Tipifarnib, and KO-2806. The Ziftomenib is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene for the treatment of genetically defined acute myeloid leukemia (AML) patients. Tipifarnib is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. KO-2806, is a next generation farnesyl transferase inhibitor (FTI), which it demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.